ShuChen Lin1, ZhiHua Gan, Kun Han, Yang Yao, DaLiu Min. 1. Department of Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai - People's Republic of China.
Abstract
AIMS AND BACKGROUND: Interleukin-6 (IL-6) has been shown to promote tumor survival, metastasis, and angiogenesis, in addition to possessing antitumor activities. In light of the conflicting data, we sought to determine whether IL-6 could be used as a prognostic factor for patients with breast cancer. METHODS: Eligible studies describing the use of IL-6 as a prognostic factor for breast cancer were identified. Data describing overall survival (OS), disease-free survival (DFS), and clinicopathologic features were collected and analyzed. RESULTS: Thirteen articles containing 3,224 breast cancer patients were identified. The results showed that IL-6 expression was not associated with lymph node metastasis, tumor size, or histologic grade. Moreover, there was no correlation between IL-6 expression and DFS. However, the combined hazard ratio (95% confidence interval) for OS was 2.15 (1.46, 3.17). Sensitivity analysis further demonstrated that, for OS, the results of this meta-analysis were stable. A subgroup analysis showed that the source used to detect IL-6 levels may have altered the pooled results for OS. CONCLUSIONS: Taken together, these results indicate that IL-6 expression is associated with poor prognosis for breast cancer and the prognostic role is affected by the source used to detect IL-6 levels.
AIMS AND BACKGROUND:Interleukin-6 (IL-6) has been shown to promote tumor survival, metastasis, and angiogenesis, in addition to possessing antitumor activities. In light of the conflicting data, we sought to determine whether IL-6 could be used as a prognostic factor for patients with breast cancer. METHODS: Eligible studies describing the use of IL-6 as a prognostic factor for breast cancer were identified. Data describing overall survival (OS), disease-free survival (DFS), and clinicopathologic features were collected and analyzed. RESULTS: Thirteen articles containing 3,224 breast cancerpatients were identified. The results showed that IL-6 expression was not associated with lymph node metastasis, tumor size, or histologic grade. Moreover, there was no correlation between IL-6 expression and DFS. However, the combined hazard ratio (95% confidence interval) for OS was 2.15 (1.46, 3.17). Sensitivity analysis further demonstrated that, for OS, the results of this meta-analysis were stable. A subgroup analysis showed that the source used to detect IL-6 levels may have altered the pooled results for OS. CONCLUSIONS: Taken together, these results indicate that IL-6 expression is associated with poor prognosis for breast cancer and the prognostic role is affected by the source used to detect IL-6 levels.
Authors: Su-Hyeong Kim; Eun-Ryeong Hahm; Julie A Arlotti; Suman K Samanta; Michelle B Moura; Stephen H Thorne; Yongli Shuai; Carolyn J Anderson; Alexander G White; Anna Lokshin; Joomin Lee; Shivendra V Singh Journal: Breast Cancer Res Treat Date: 2016-04-21 Impact factor: 4.872
Authors: Amy L Strong; Dorothy T Pei; Christian G Hurst; Jeffrey M Gimble; Matthew E Burow; Bruce A Bunnell Journal: Stem Cells Int Date: 2017-12-17 Impact factor: 5.443
Authors: Chike O Abana; Brian S Bingham; Ju Hwan Cho; Amy J Graves; Tatsuki Koyama; Robert T Pilarski; A Bapsi Chakravarthy; Fen Xia Journal: PLoS One Date: 2017-07-21 Impact factor: 3.240
Authors: Daniel T Dibaba; Suzanne E Judd; Susan C Gilchrist; Mary Cushman; Maria Pisu; Monika Safford; Tomi Akinyemiju Journal: Metabolism Date: 2019-02-23 Impact factor: 8.694